KPTI Karyopharm Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KPTI

Price (delayed)

$1.035

Market cap

$119.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.25

Enterprise value

$242.92M

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related ...

Highlights
The EPS has grown by 38% YoY and by 4.6% from the previous quarter
The net income has grown by 13% YoY but it has contracted by 2.4% from the previous quarter
Karyopharm Therapeutics's quick ratio has decreased by 36% YoY and by 21% from the previous quarter
The equity has contracted by 36% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://karyopharm.com
Peers: MRK BMY ABT EXEL

Key stats

What are the main financial stats of KPTI
Market
Shares outstanding
115.07M
Market cap
$119.09M
Enterprise value
$242.92M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.66
Earnings
Revenue
$146.03M
EBIT
-$118.95M
EBITDA
-$118.42M
Free cash flow
-$92.72M
Per share
EPS
-$1.25
Free cash flow per share
-$0.81
Book value per share
-$1.19
Revenue per share
$1.28
TBVPS
$2.11
Balance sheet
Total assets
$240.44M
Total liabilities
$376.64M
Debt
$177.02M
Equity
-$136.21M
Working capital
$164.44M
Liquidity
Debt to equity
-1.3
Current ratio
3.37
Quick ratio
3.16
Net debt/EBITDA
-1.05
Margins
EBITDA margin
-81.1%
Gross margin
96.6%
Net margin
-98%
Operating margin
-88.7%
Efficiency
Return on assets
-50.5%
Return on equity
N/A
Return on invested capital
-35.8%
Return on capital employed
-69.6%
Return on sales
-81.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KPTI stock price

How has the Karyopharm Therapeutics stock price performed over time
Intraday
-2.36%
1 week
-11.54%
1 month
-25.54%
1 year
-71.17%
YTD
19.65%
QTD
-31.46%

Financial performance

How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$146.03M
Gross profit
$141.09M
Operating income
-$129.54M
Net income
-$143.1M
Gross margin
96.6%
Net margin
-98%
The net income has grown by 13% YoY but it has contracted by 2.4% from the previous quarter
KPTI's operating income is up by 9% YoY but it is down by 3.1% QoQ
The revenue has contracted by 7% YoY
KPTI's net margin is up by 7% YoY but it is down by 2.3% from the previous quarter

Growth

What is Karyopharm Therapeutics's growth rate over time

Valuation

What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.66
The EPS has grown by 38% YoY and by 4.6% from the previous quarter
The equity has contracted by 36% from the previous quarter
The P/S is 92% lower than the 5-year quarterly average of 9.8 and 45% lower than the last 4 quarters average of 1.5
The revenue has contracted by 7% YoY

Efficiency

How efficient is Karyopharm Therapeutics business performance
Karyopharm Therapeutics's return on invested capital has increased by 26% YoY but it has decreased by 6% QoQ
KPTI's ROA is down by 13% QoQ but it is up by 13% YoY
The ROS has grown by 9% YoY but it has contracted by 2.5% from the previous quarter

Dividends

What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KPTI.

Financial health

How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 36% smaller than its total liabilities
The current ratio has contracted by 37% YoY and by 21% from the previous quarter
Karyopharm Therapeutics's quick ratio has decreased by 36% YoY and by 21% from the previous quarter
KPTI's debt to equity has surged by 88% year-on-year and by 27% since the previous quarter
The equity has contracted by 36% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.